Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2011 Oct;128(4):729-39.
doi: 10.1542/peds.2010-2725. Epub 2011 Sep 19.

Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials

Lisa M Askie  1 , Roberta A Ballard, Gary R Cutter, Carlo Dani, Diana Elbourne, David Field, Jean-Michel Hascoet, Anna Maria Hibbs, John P Kinsella, Jean-Christophe Mercier, Wade Rich, Michael D Schreiber, Pimol Srisuparp Wongsiridej, Nim V Subhedar, Krisa P Van Meurs, Merryn Voysey, Keith Barrington, Richard A Ehrenkranz, Neil N Finer; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration
Collaborators, Affiliations
Meta-Analysis

Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials

Lisa M Askie et al. Pediatrics. 2011 Oct.

Abstract

Background: Inhaled nitric oxide (iNO) is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants. Fourteen randomized controlled trials (n = 3430 infants) have been conducted on preterm infants at risk for chronic lung disease (CLD). The study results seem contradictory.

Design/methods: Individual-patient data meta-analysis included randomized controlled trials of preterm infants (<37 weeks' gestation). Outcomes were adjusted for trial differences and correlation between siblings.

Results: Data from 3298 infants in 12 trials (96%) were analyzed. There was no statistically significant effect of iNO on death or CLD (59% vs 61%: relative risk [RR]: 0.96 [95% confidence interval (CI): 0.92-1.01]; P = .11) or severe neurologic events on imaging (25% vs 23%: RR: 1.12 [95% CI: 0.98-1.28]; P = .09). There were no statistically significant differences in iNO effect according to any of the patient-level characteristics tested. In trials that used a starting iNO dose of >5 vs ≤ 5 ppm there was evidence of improved outcome (interaction P = .02); however, these differences were not observed at other levels of exposure to iNO. This result was driven primarily by 1 trial, which also differed according to overall dose, duration, timing, and indication for treatment; a significant reduction in death or CLD (RR: 0.85 [95% CI: 0.74-0.98]) was found.

Conclusions: Routine use of iNO for treatment of respiratory failure in preterm infants cannot be recommended. The use of a higher starting dose might be associated with improved outcome, but because there were differences in the designs of these trials, it requires further examination.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Primary outcomes. All P > .05 (χ2 test for heterogeneity). RRs, CIs, and P values were derived from 1000 iterations of a log-binomial model using the multiple-outputation method.
FIGURE 2
FIGURE 2
Secondary outcomes. RRs, CIs, and P values were derived from 1000 iterations of a log-binomial model using the multiple-outputation method. a χ2 test for heterogeneity: P = .04; all other P > .05. IVH indicates intraventricular hemorrhage; ROP, retinopathy of prematurity.
FIGURE 3
FIGURE 3
Death or CLD according to subgroup. All P > .05 for subgroup-by-treatment interaction effects. Estimates were derived from 1000 iterations of a Poisson regression model with robust error variance using the multiple-outputation method. PDA indicates patent ductus arteriosus.
FIGURE 4
FIGURE 4
Severe neurologic events according to subgroup. All P > .05 for subgroup-by-treatment interaction effects. Estimates were derived from 1000 iterations of a Poisson regression model with robust error variance using the multiple-outputation method. PDA indicates patent ductus arteriosus.
FIGURE 5
FIGURE 5
Death or CLD according to dosage. Estimates were derived from 1000 iterations of a Poisson regression model with robust error variance using the multiple-outputation method.
FIGURE 6
FIGURE 6
Death or CLD according to trial. All P > .05 (χ2 test for heterogeneity). Estimates were derived from 1000 iterations of a log-binomial model using the multiple-outputation method.
See this image and copyright information in PMC

Comment in

References

    1. Australian and New Zealand Neonatal Network Report of the Australian and New Zealand Neonatal Network 2006. Sydney, Australia: Australian and New Zealand Neonatal Network; 2009
    1. Furdon SA, Clark DA. Prematurity. Available at: http://emedicine.medscape.com/article/975909-overview Accessed March 16, 2010
    1. Fanaroff AA, Stoll BJ, Wright LL, et al. ; NICHD Neonatal Research Network Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196(2):147.e1–147.e8 - PubMed
    1. Bhandari A, Bhandari V. Bronchopulmonary dysplasia: an update. Indian J Pediatr. 2007;74(1):73–77 - PubMed
    1. Schmidt B, Asztalos E, Roberts R, Robertson C, Sauve R, Whitfield M. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the Trial of Indomethacin Prophylaxis in Preterms. JAMA. 2003;289(9):1124–1129 - PubMed

Publication types

MeSH terms